Empagliflozin(W.S); Empaglifloin; Empagliflozin API; BI-10773; BI 10773; BI10773; CS-798; EMPAGLIFLBZIN
CAS: 864070-44-0
Chemical Formula: C23H27ClO7
MW: 450.91
Availability: R&D; Commercialization
⬤ CAS No. 864070-44-0
⬤ Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| Product Name | Empagliflozin |
| CAS No. | 864070-44-0 |
| Chemical Formula | C23H27ClO7 |
| Molecular Weight | 450.91 |
| Related Categories | Empagliflozin; APIs and intermediates; hypoglycemics; Empagliflozin API; APIs; hypoglycemics; small molecule inhibitors; pharmaceutical APIs; hypoglycemics |
| EINECS | 620-176-8 |
| Melting point | 665℃ |
| Storage conditions | 2-8°C |
| Solubility | Insoluble in water; ≥20.75 mg/mL in DMSO; ≥7.06 mg/mL in ethanol solution, ultrasonic |
| Form | Solid |
| Color | White |
| Density | 1.398 |
| Stability | Hygroscopicity |
| Flash point | 356℃ |
| Acidity coefficient (pKa) | 13.23±0.70(Predicted) |
| Product Name | Empagliflozin |
| Hazard Statements | H317: May cause an allergic skin reaction. H319: Causes serious eye irritation. |
| Precautionary Statements | P261: Avoid breathing dust/fume/gas/mist/vapours/spray.P272: Contaminated work clothing should not be allowed out of the workplace. |
| Main Component | Empagliflozin (SGLT2 inhibitor) |
| Concentration | 100% (active pharmaceutical ingredient) |
| Stability Conditions | Store in a well-ventilated area, away from heat and moisture. |
| Incompatibility | Avoid contact with strong oxidizing agents. |
| Conditions to Avoid | Exposure to moisture, heat, and direct sunlight. |
| Routes of Exposure | Inhalation, ingestion, skin contact |
| Effects | May cause skin irritation, eye irritation, allergic reactions. Consult medical advice if swallowed. |
| First Aid Measures | Eye contact: Rinse immediately with plenty of water. Skin contact: Wash with soap and water. Ingestion: Seek medical attention. |
| Handling Precautions | Wear appropriate protective clothing and gloves. Avoid prolonged skin contact. |
| Storage Conditions | Store in a cool, dry place, protected from light. Keep container tightly closed. |
| Personal Protective Equipment | Protective clothing, gloves, and eye protection during handling. |
| Waste Disposal | Dispose of in accordance with local regulations and waste management guidelines. |
| Overview | Empagliflozin is a sodium-dependentglucose cotransporter 2 (SGLT-2) inhibitor. SGLT-2 inhibitors are a new type of hypoglycemic drug that mainly inhibits SGLT-2 expressed in the kidney, reduces glucose reabsorption by the kidney, increases glucose excretion in the urine, and thus reduces plasma glucose levels. Its hypoglycemic effect is independent of β-cell function and insulin resistance. |
| Empagliflozin | It is used to treat adult patients with type 2 diabetes who have not achieved adequate glycemic control with diet and exercise to improve glycemic control. |
| Adverse Reactions | Empagliflozin has a low incidence of adverse reactions. Compared with the placebo group, the incidence of common adverse reactions was 2%, including urinary tract infection, female reproductive system fungal infection, upper respiratory tract infection, polyuria, dyslipidemia, joint pain, male reproductive system fungal infection, hypoglycemia, and nausea. Other adverse reactions less than 2% are common in thirst (polydipsia, polydipsia), hypovolemia, and renal impairment. |
Exceptional Product Quality
“We have been sourcing pharmaceuticals from Tianming Pharmaceutical for several years now, and their product quality has consistently exceeded our expectations. Each batch undergoes rigorous testing, ensuring we receive only the highest quality products. This reliability has significantly contributed to our trust and satisfaction with their services. Highly recommended!”
June 15, 2023
Outstanding Technical Guidance
“The technical guidance provided by Tianming Pharmaceutical’s team has been invaluable to our research and development projects. Their experts are knowledgeable, responsive, and always willing to assist with detailed explanations and support. Their guidance has enabled us to optimize our processes and achieve remarkable results. We couldn’t ask for a better partner.”
June 15, 2023
Superior Service Experience
“Our experience with Tianming Pharmaceutical has been nothing short of excellent. Their customer service team is exceptionally responsive and dedicated to meeting our needs. From initial consultation to after-sales support, they have provided seamless, professional service. Their commitment to customer satisfaction is truly commendable.”
June 15, 2023
Precise Product Specifications
“Tianming Pharmaceutical has impressed us with their adherence to precise product specifications. Each order is meticulously packaged and delivered exactly as requested, ensuring that we receive products that perfectly meet our requirements. Their attention to detail and commitment to accuracy have made them a trusted supplier for our business.”
June 15, 2023
Orforglipron vs retatrutide: oral small‑molecule GLP‑1 agonist vs triple‑hormone injectable. Phase 3 weight loss data, dosing schedules, side effects, regulatory status, and API manufacturing differences.
Regulatory differences between API and intermediate manufacturing under ICH Q7, FDA, EMA, and NMPA. GMP boundaries, DMF filing, starting material justification.
Finerenone drug class: third‑generation non‑steroidal MRA. Compare selectivity, potency, half‑life, and safety vs spironolactone/eplerenone. FDA‑approved for CKD+T2D and HF with LVEF ≥40%.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.
